346,705 results on '"Breast neoplasms"'
Search Results
152. Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
153. A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12)
154. CARE: Cancer Risk Perception and Women of Color
155. Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
156. Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
157. Patient's Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer (CARTE)
158. Lymphedema Surveillance Study
159. Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
160. Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
161. Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer (LB1802)
162. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
163. Axillary Management in Breast Cancer Patients with Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy (ATNEC)
164. Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
165. HIIT Following Breast Cancer Chemotherapy
166. Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
167. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
168. A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
169. Partial Irradiation and Sequential Vs. Concurrent Chemo Early Breast Cancer
170. UNFOLD Study Egypt
171. Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)
172. Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial
173. DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients with Triple Negative Breast Cancer
174. Appetite and Exercise in Breast Cancer Survivors (EARNESt)
175. Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)
176. One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer (HYPORTAdjuvant)
177. OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes (OPTImaL)
178. Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
179. Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (NAOMI)
180. Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
181. Promoting Resilience in Women with Breast Cancer (PRISM)
182. Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial (MIMOSA)
183. Dermatitis During Adjuvant Irradiation for BREAst Cancer (DAI-BREAC)
184. SMART-ER: Symptom Monitoring With Patient-reported Outcomes (SMART-ER)
185. Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients (Chemosense)
186. Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
187. Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
188. Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer
189. Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer (VISION I)
190. Prospective Breast Cancer Biospecimen Collection
191. A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
192. Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
193. Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer (EASOVCWDITHABC)
194. Effectiveness of Self-Physiotherapy in the Management of Lymphedema
195. Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer
196. Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer (ONCO-Adher)
197. A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC)
198. M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
199. A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
200. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.